Efficacy and safety of cariprazine in bipolar I depression: A double‐blind, placebo‐controlled phase 3 study

Cariprazine Treatment of Bipolar Depression: A Randomized Double-Blind Placebo-Controlled Phase 3 Study

(2019) Willie Earley et al.   AMERICAN JOURNAL OF PSYCHIATRY

Efficacy of adjunctive low-dose cariprazine in major depressive disorder

(2018) Maurizio Fava et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

An 8-Week Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Cariprazine in Patients With Bipolar I Depression

(2016) Suresh Durgam et al.   AMERICAN JOURNAL OF PSYCHIATRY

Agomelatine or placebo as adjunctive therapy to a mood stabiliser in bipolar I depression: Randomised double-blind placebo-controlled trial

(2016) Lakshmi N. Yatham et al.   BRITISH JOURNAL OF PSYCHIATRY

Efficacy of cariprazine on predominant negative symptoms of patients with schizophrenia: post hoc analysis of PANSS data, Marder factors, and cognition

(2016) S. Marder et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

An update of safety of clinically used atypical antipsychotics

(2016) L. Orsolini et al.   Expert Opinion On Drug Safety

Efficacy and Safety of Adjunctive Cariprazine in Inadequate Responders to Antidepressants

(2016) Suresh Durgam et al.   JOURNAL OF CLINICAL PSYCHIATRY

Cariprazine in the treatment of acute mania in bipolar I disorder: A double-blind, placebo-controlled, Phase III trial

(2015) Gary S. Sachs et al.   JOURNAL OF AFFECTIVE DISORDERS

Association of obesity and treated hypertension and diabetes with cognitive ability in bipolar disorder and schizophrenia

(2014) Colin A Depp et al.   BIPOLAR DISORDERS

Managing the side effects associated with commonly used treatments for bipolar depression

(2014) David E. Kemp   JOURNAL OF AFFECTIVE DISORDERS

Lurasidone Monotherapy in the Treatment of Bipolar I Depression: A Randomized, Double-Blind, Placebo-Controlled Study

(2013) Antony Loebel et al.   AMERICAN JOURNAL OF PSYCHIATRY

Minimum clinically important differences identified for commonly used depression rating scales

(2013) Sarah C. Masson et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression

(2012) Mauricio Tohen et al.   BRITISH JOURNAL OF PSYCHIATRY

Two 6-Week, Randomized, Double-Blind, Placebo-Controlled Studies of Ziprasidone in Outpatients With Bipolar I Depression

(2012) Ilise Lombardo et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

The Columbia–Suicide Severity Rating Scale: Initial Validity and Internal Consistency Findings From Three Multisite Studies With Adolescents and Adults

(2011) Kelly Posner et al.   AMERICAN JOURNAL OF PSYCHIATRY

Efficacy and Safety of Adjunctive Oral Ziprasidone for Acute Treatment of Depression in Patients With Bipolar I Disorder

(2011) Gary S. Sachs et al.   JOURNAL OF CLINICAL PSYCHIATRY

A Double-Blind, Placebo-Controlled Study of Quetiapine and Paroxetine as Monotherapy in Adults With Bipolar Depression (EMBOLDEN II)

(2010) Susan L. McElroy et al.   JOURNAL OF CLINICAL PSYCHIATRY

A Double-Blind, Placebo-Controlled Study of Quetiapine and Lithium Monotherapy in Adults in the Acute Phase of Bipolar Depression (EMBOLDEN I)

(2010) Allan H. Young et al.   JOURNAL OF CLINICAL PSYCHIATRY

In vitro and in vivo comparison of [3H](+)-PHNO and [3H]raclopride binding to rat striatum and lobes 9 and 10 of the cerebellum: A method to distinguish dopamine D3 from D2 receptor sites: A method to distinguish dopamine D3 from D2 receptor sites

(2010) Béla Kiss et al.   SYNAPSE

Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression

(2009) Trisha Suppes et al.   JOURNAL OF AFFECTIVE DISORDERS

Aripiprazole Monotherapy in Nonpsychotic Bipolar I Depression

(2009) Michael E. Thase et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials

(2008) Joseph R Calabrese et al.   BIPOLAR DISORDERS

Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics

(2008) Christoph U Correll et al.   BIPOLAR DISORDERS